NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading ALMS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. ALMS is currently loss-making but is focused on advancing its clinical pipeline and submitting a New Drug Application, which could drive future growth.
The market seems to be pricing in a significant premium compared to peers, reflecting a high level of optionality in ALMS's future. However, there is a low confidence in the valuation model, indicating uncertainty in future performance.
Management's focus on key regulatory milestones and funding operations through 2027 suggests a stable approach despite current losses. Recent earnings beats indicate some positive momentum, but the overall financial performance remains neutral.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as their results will influence ALMS's trajectory. Additionally, any guidance cuts or misses could negatively impact sentiment and expectations.
Over the next 1 to 3 years, ALMS's prospects will depend on its ability to navigate regulatory milestones and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Submitting the NDA is crucial for Alumis to advance its drug pipeline. It shows commitment to growth.
Confirms:The company submits the New Drug Application to the FDA in H2 2026 as planned.
Disproves:The company delays the NDA submission beyond H2 2026.
Why it matters: Funding updates will show if the company can keep running until Q4 2027.
Confirms:The company says it has enough cash and funds from the offering to operate.
Disproves:The company says it needs more funding before Q4 2027.
Why it matters: Alumis needs funding to keep its projects going. This affects its financial health and growth.
Confirms one read:Management says cash will last until Q4 2027 without more funding.
Confirms the other:Management says more funding is needed before Q4 2027.
Why it matters: Starting this trial is important for Alumis's growth and clinical plans.
Confirms:The company initiates the Phase 2 biomarker trial for A-005 in Parkinson’s disease in 1H 2027.
Disproves:The company delays the initiation of the Phase 2 biomarker trial beyond 1H 2027.
Why it matters: If health care revenue growth picks up, it may help Alumis improve its performance.
Confirms:Health care revenue growth speeds up to 10% or more.
Disproves:Health care revenue growth keeps slowing down below current levels.
Why it matters: This data will show progress in the clinical pipeline and could impact future funding and growth.
Confirms one read:The company reports positive topline data from the Phase 2b SLE trial.
Confirms the other:The company reports negative topline data from the Phase 2b SLE trial.
Why it matters: Funding operations is crucial for Alumis. Monitoring cash burn will show if they can sustain operations.
Confirms:Cash burn remains below $5 million per quarter through Q4 2027.
Disproves:Cash burn is over $5 million each quarter. This shows financial strain.
Why it matters: Submitting the New Drug Application is key for Alumis to advance its drug pipeline. It could attract investor interest and funding.
Confirms:A press release confirming the submission of the New Drug Application to the FDA.
Disproves:No submission announcement by the end of H2 2026.
Why it matters: The outcome of the litigation could affect Alumis's financial health and reputation. It is a risk factor for investors.
Confirms:A resolution or settlement in the lawsuit that helps Alumis.
Disproves:Bad news in the lawsuit that hurts Alumis's position.
Why it matters: Funding operations until Q4 2027 is key for stability. It shows management can handle cash.
Confirms:Management says current cash and the January 2026 offering will pay for operations. This will last until Q4 2027.
Disproves:Management warns of a need for more funding or cash flow problems before Q4 2027.
Why it matters: Earnings results will show if Alumis can improve its loss-making status. This is key for investor confidence.
Confirms one read:The earnings report shows smaller losses or a way to make money.
Confirms the other:The earnings report shows bigger losses or no clear way to make money.
Why it matters: Starting this trial could show progress in Alumis' pipeline. It may also create new revenue.
Confirms:Phase 1 trial for the new candidate begins as planned in 2H 2026.
Disproves:Phase 1 trial for the new candidate is delayed or not initiated in 2H 2026.
